Engineering an ACE2-Derived Fragment as a Decoy for Novel SARS-CoV-2 Virus

Area of Science:

• Virology and Structural Biology
• Drug Discovery and Development

Background:

• Emerging viral pathogens like SARS-CoV-2 pose significant global health threats.
• Viral entry into host cells, mediated by surface proteins like the SARS-CoV-2 spike glycoprotein binding to cellular receptors such as angiotensin-converting enzyme 2 (ACE2), is a critical step in infection.
• Developing effective entry inhibitors is crucial for combating viral infections.

Purpose of the Study:

• To identify and design a novel therapeutic agent that can inhibit SARS-CoV-2 entry into human cells.
• To develop a stable peptide-based decoy that specifically disrupts the interaction between the SARS-CoV-2 spike protein and the ACE2 receptor.

Main Methods:

• Comparative structural analyses of the spike-ACE2 binding interface.
• Computational docking experiments to predict binding affinities.
• Molecular dynamics simulations to assess stability and interactions.
• Experimental validation of designed peptides.

Main Results:

• Identification of a stable, soluble ACE2 fragment that binds to the SARS-CoV-2 spike protein.
• Computational design and experimental validation of a smaller peptide derived from this fragment.
• The designed peptide effectively disrupts the spike-ACE2 interaction at nanomolar concentrations.

Conclusions:

• A novel, stable peptide has been developed that acts as a potent inhibitor of SARS-CoV-2 cell entry.
• This peptide functions as a decoy, competitively interfering with viral binding to ACE2.
• The findings suggest promising potential for this peptide as a therapeutic strategy against SARS-CoV-2 infection.